Internship
Information Technology System Integration Apprentice
Sartorius
1,001-5,000 employees
Bioprocess and laboratory solutions provider
Compensation Overview
€1.2k - €1.3k/mo
Guxhagen, Germany
In Person
 IT & Security (1) |
|---|
Get referred to Sartorius
See people who can refer or advise you
- Good prior knowledge of information technology and a strong interest in information technology are required.
- Good knowledge of mathematics, physics, and English, together with an interest in economic relationships, is required.
- Analytical and logical thinking skills are required.
- A structured approach to work and high flexibility are required.
- Enjoyment of collaborating in international teams is required.
- Work in various departments according to a structured training plan and learn organizational workflows and processes.
- Participate in frequently international projects.
- Develop concepts and implement customer-specific information and communication solutions.
- Install and network complex systems, applications, and hardware components, and analyze and support them.
- Advise and train users.
- Attend regular workshops, internal instruction, and structured examination preparation to support personal and professional development.
Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Göttingen, Germany
Founded
1870
Get referred to Sartorius
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales rose 7.7%, and management confirmed full-year guidance on August 11, 2026.
- Bioprocess Solutions grew 8.3% in H1 2026, with consumables offsetting equipment normalization.
- May 2026 bond refinancing cut funding pressure, supporting capacity expansion and acquisitions.
What critics are saying
- Lab Products grew 0.2% in 2025, exposing weak diversification beyond bioprocessing.
- Advanced-therapy orders slipped from two customers in H1 2026, delaying revenue into 2027.
- Tariff surcharges, €26 million compensation, and higher leverage keep earnings vulnerable through 2026.
What makes Sartorius unique
- Sartorius dominates single-use bioprocessing through Stedim, consumables, and installed-base switching costs.
- Its 2026 Eveo platform bundles cell selection, gene editing, expansion, and QC.
- MatTek adds 3D microtissue models, strengthening Sartorius across drug development workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget
Company News
Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.
Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.
Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.
May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.
Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.